Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 18, Issue 3, Pages 311-325Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780902752463
Keywords
antibody; apoptosis; humans; mapatumumab; Phase I trials; TRAIL
Categories
Ask authors/readers for more resources
In spite of the advances in survival with chemotherapy and radiotherapy, many cancer patients continue to experience failure with treatments. Advances in molecular oncology and the development of numerous targeted therapies, used by themselves or in combination with at present available treatments such as chemotherapy and radiation, will hopefully improve the fate of these patients. It has been well understood for many years now that deregulation of apoptosis is a major hallmark of cancer cells. Mapatumumab, a fully human agonistic monoclonal antibody to TNF-related apoptosis-inducing ligand receptor 1, has been developed to induce apoptosis in cancer cells although having minimal effects on normal cells. This paper reviews the preclinical and early clinical data of this exciting new agent and discusses options for future development of mapatumumab, mostly in combinations with other therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available